Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events.

CONCLUSION: Systemic RV is difficult to treat effectively. Complete remission of RV was achieved in 62% and partial response in 38% of patients within 12 months of rituximab use. Further evidence is needed to inform treatment for patients with RV. PMID: 31203225 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31203225?dopt=Abstract

Source: J Rheumatol - June 14, 2019 Category: Rheumatology Authors: Coffey CM, Richter MD, Crowson CS, Koster MJ, Warrington KJ, Ytterberg SR, Makol A Tags: J Rheumatol Source Type: research

More News: Rheumatology | Rituxan | Skin | Study | Vasculitis